Login to Your Account

Phaserx eyes transaction to advance urea iERT bid

By Randy Osborne
Staff Writer

Tuesday, November 28, 2017

Phaserx Inc. CEO Robert Overell told BioWorld the firm has paused its lead, preclinical effort in intracellular enzyme replacement therapy (iERT) as the search continues for "a strategic transaction, including a potential merger" to advance the pipeline.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription